Anti-leukemic effect of CDK9 inhibition in T-cell prolymphocytic leukemia.
CDK9 inhibitor
T-cell prolymphocytic leukemia
atuveciclib
venetoclax
Journal
Therapeutic advances in hematology
ISSN: 2040-6207
Titre abrégé: Ther Adv Hematol
Pays: England
ID NLM: 101549589
Informations de publication
Date de publication:
2020
2020
Historique:
received:
05
10
2019
accepted:
19
05
2020
entrez:
29
10
2020
pubmed:
30
10
2020
medline:
30
10
2020
Statut:
epublish
Résumé
T-cell prolymphocytic leukemia (T-PLL) is an aggressive malignancy characterized by chemotherapy resistance and a median survival of less than 2 years. Here, we investigated the pharmacological effects of the novel highly specific cyclin-dependent kinase 9 (CDK9) inhibitor LDC526 and its clinically used derivate atuveciclib employing primary T-PLL cells in an
Identifiants
pubmed: 33117517
doi: 10.1177/2040620720933761
pii: 10.1177_2040620720933761
pmc: PMC7570784
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2040620720933761Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: SM, PH, BK, and AC are employees of the Lead Discovery Center GmbH (LDC). PH, AC, and BK furthermore are co-inventors of the patent family for LDC526 and atuveciclib. These patents have been licensed to Bayer AG.
Références
ChemMedChem. 2017 Nov 8;12(21):1776-1793
pubmed: 28961375
Cell Rep. 2017 Sep 19;20(12):2833-2845
pubmed: 28930680
Blood. 2017 Dec 7;130(23):2499-2503
pubmed: 28972014
Nat Commun. 2016 Jun 21;7:11702
pubmed: 27325363
Sci Rep. 2019 Mar 1;9(1):3197
pubmed: 30824765
Leukemia. 2007 Oct;21(10):2153-63
pubmed: 17713554
Leukemia. 2015 Apr;29(4):798-806
pubmed: 25231743
Genome Res. 2003 Aug;13(8):1863-72
pubmed: 12902380
Blood Cancer J. 2018 Jan 19;8(1):11
pubmed: 29352181
Br J Cancer. 2014 Oct 14;111(8):1572-80
pubmed: 25117811
J Clin Oncol. 2018 Apr 1;36(10):1007-1016
pubmed: 29432078
Oncotarget. 2018 May 29;9(41):26353-26369
pubmed: 29899864
Leuk Res. 2015 May;39(5):495-500
pubmed: 25804339
Mol Med Rep. 2016 Jan;13(1):273-80
pubmed: 26573378
Leukemia. 2018 Aug;32(8):1807-1810
pubmed: 29479063
J Cell Physiol. 2010 Jan;222(1):200-8
pubmed: 19780058
Bone Marrow Transplant. 2019 Sep;54(9):1391-1398
pubmed: 30664723
Blood. 2014 Aug 28;124(9):1460-72
pubmed: 24825865
Leukemia. 2018 Mar;32(3):774-787
pubmed: 28804127
J Clin Invest. 2018 Jan 2;128(1):427-445
pubmed: 29227286
Anticancer Res. 2019 Feb;39(2):557-565
pubmed: 30711930
Nat Commun. 2017 Jan 30;8:14290
pubmed: 28134252
Genes Chromosomes Cancer. 2014 Apr;53(4):309-16
pubmed: 24446122
Cell. 2018 Nov 15;175(5):1244-1258.e26
pubmed: 30454645
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Br J Pharmacol. 2014 Jan;171(1):55-68
pubmed: 24102143
Cancer Lett. 2019 Apr 1;446:81-89
pubmed: 30660651
Blood. 2011 Nov 24;118(22):5799-802
pubmed: 21948296
Mol Cancer. 2018 Aug 7;17(1):115
pubmed: 30086763
Oncotarget. 2017 Jun 19;8(39):66360-66370
pubmed: 29029518
Hematology Am Soc Hematol Educ Program. 2015;2015:361-7
pubmed: 26637744
Oncogene. 2010 Apr 29;29(17):2477-87
pubmed: 20140016
Nat Commun. 2018 Feb 15;9(1):697
pubmed: 29449575
Nucleic Acids Res. 2007 Jul;35(Web Server issue):W186-92
pubmed: 17526521